The BMP2K Knockout HCT 116 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the BMP2K gene in the human HCT 116 colorectal carcinoma cell line. This heterogeneous pool of edited cells offers a robust loss-of-function model for studying BMP2K-dependent signaling and endocytic regulation, providing an experimentally flexible alternative to clonal lines. The lack of single-cell cloning preserves genetic diversity and allows for population-level analyses that better reflect tumor heterogeneity, making them particularly suited for pooled functional genomics screens and assays requiring bulk cell responses.
HCT 116 is a widely used epithelial colorectal carcinoma line characterized by a KRAS G13D activating mutation, MLH1 deficiency that causes microsatellite instability (MSI), and wild-type p53 status. These molecular features render HCT 116 highly relevant for exploring oncogenic signaling pathways, DNA mismatch repair defects, and therapeutic vulnerabilities in MSI-high colorectal cancers. The cell line??s robust growth kinetics and compatibility with standard transfection and drug treatment protocols facilitate reproducible biochemical, imaging, and high-throughput analyses.
BMP2K (BMP-2-inducible kinase) is a serine/threonine kinase transcriptionally upregulated by BMP-2 ligand through SMAD1, SMAD5, and SMAD8 transcription factors downstream of BMP receptors BMPR1A and BMPR1B. Once expressed, BMP2K phosphorylates endocytic proteins including clathrin heavy chain (CLTC) and the AP2 adaptor complex subunits AP2B1 and AP2M1, thereby enhancing clathrin-mediated endocytosis of BMP receptors. This phosphorylation-driven internalization attenuates surface receptor levels and modulates the strength and duration of SMAD-dependent signal transduction, establishing a feedback loop that finetunes BMP pathway responsiveness. BMP2K also interacts directly with BMP receptors and SMAD proteins, positioning it at a critical nexus between ligand sensing and endocytic execution. Additionally, through its interactions with the endocytic machinery, BMP2K may influence the trafficking of other receptor tyrosine kinases, broadening its impact on cellular signaling networks.
In the colorectal cancer context, aberrant BMP signaling contributes to tumor progression, metastasis, and stem cell dynamics. Disruption of BMP2K in the MSI-high, KRAS-mutant HCT 116 background allows researchers to dissect how clathrin-mediated receptor endocytosis alters oncogenic signaling output. Given that BMP2K forms complexes with clathrin and AP2 while phosphorylating these components, its knockout is expected to impair BMP receptor internalization, potentially hyperactivating downstream SMAD signaling or altering crosstalk with other pathways such as TGF-??. Moreover, in HCT 116 cells, the KRAS G13D mutation drives constitutive MAPK activation, which may intersect with BMP2K-regulated endocytic trafficking; therefore, knocking out BMP2K can reveal synergistic or antagonistic signaling interactions relevant to colorectal tumorigenesis.
These polyclonal knockout cells can be employed in diverse applications: Western blotting to assess changes in phospho-SMAD1/5/8 levels; RT-qPCR to quantify BMP2K mRNA reduction; immunofluorescence to visualize clathrin distribution; transferrin uptake assays to directly measure clathrin-mediated endocytosis efficiency; MTT and clonogenic survival assays to evaluate cell proliferation; phospho-kinase arrays to profile global signaling alterations; and RNA-seq to capture transcriptional consequences of BMP2K loss. Additionally, these cells support drug sensitivity screens to identify compounds whose efficacy depends on BMP2K status, and can be adapted for xenograft models to study tumor growth and metastasis upon BMP2K loss. For further information, please contact Ascent Research.
